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List	of	abbreviations	
 
ADC	 apparent	diffusion	coefficient	
AML	 angiomyolipoma	
BOLD	 blood	oxygen	level-dependent		
ccRCC	 clear	cell	renal	cell	carcinoma	
CECT	 contrast-enhanced	computed	tomography	
CE	MRI	 contrast-enhanced	magnetic	resonance	imaging	
CEUS	 contrast-enhanced	ultrasound	
chRCC	 chromophobe	renal	cell	carcinoma	
DCE	 dynamic	contrast-enhanced	
DTA	 diagnostic	test	accuracy	
DW	 diffusion-weighted	
EAU	 European	Association	of	Urology	
FDG	 fludeoxyglucose	
IQR	 interquartile	range	
MRI	 magnetic	resonance	imaging	
NPV	 negative	predictive	value	
PDUS	 power	Doppler	ultrasound	
PET/CT	 positron	emission	tomography-computed	tomography	
PICO	 population,	intervention,	comparison	and	outcomes	
PPV	 positive	predictive	value	
pRCC	 papillary	renal	cell	carcinoma	
PRISMA	 Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-Analyses	
QUADAS	 Quality	Assessment	of	Diagnostic	Accuracy	Studies	
RCC	 renal	cell	carcinoma	
SRM	 small	renal	masses	(≤	4	cm)	
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1.	Introduction	
	
1.1	Renal	cell	carcinoma	
	
The	 incidence	of	 renal	 cell	 carcinoma	 (RCC)	 is	 still	 rising	 in	most	 countries	of	 the	
world.	 At	 the	 same	 time	 stabilisation	 or	 even	 decrease	 of	 mortality	 has	 been	
accomplished	in	many	countries	of	Europe	and	North	America	[1].	On	the	one	hand,	
these	trends	can	be	explained	by	the	increase	of	incidentally	detected	renal	masses	
with	better	prognosis	owing	to	the	widespread	use	of	ultrasound	and	CT	[2,	3].	On	
the	 other	 hand,	 the	 availability	 of	 improved	 therapeutic	 measures	 in	 highly	
developed	countries	has	led	to	declining	mortality	trends	[1].	
With	an	estimated	338,000	new	cases	of	kidney	cancer	in	2012	it	constitutes	2-3%	
of	all	cancer	cases	worldwide	[4].	Rates	vary	strongly,	with	the	highest	incidence	in	
Western	countries	[1].		
RCC	represents	more	than	90%	of	these	malignant	renal	tumours	[5].	The	three	main	
histologic	 types	 are	 clear	 cell,	 papillary	 and	 chromophobe	 RCC	 [6].	 Risk	 factors	
include	 tobacco	 smoking,	 obesity,	 hypertension	 and	 a	 positive	 family	 history	 for	
renal	cancer	 [7].	A	protective	effect	has	been	reported	for	a	diet	rich	 in	 fruit	and	
vegetables	[7]	as	well	as	for	moderate	alcohol	consumption	[8].	There	are	a	number	
of	 genetic	 cancer	 syndromes	 associated	 with	 RCC,	 such	 as	 Von-Hippel-Lindau	
disease,	 hereditary	 papillary	 renal	 cell	 carcinoma,	 hereditary	 leiomyomatosis	 and	
renal	cell	cancer	and	Birt-Hogg-Dubé	syndrome	[5].	
Clinically,	the	classic	triad	of	gross	haematuria,	flank	pain	and	abdominal	mass	has	
become	rare	[3].	Other	possible	clinical	manifestations	include	systemic	symptoms	
such	as	anorexia,	fever,	abdominal	pain	or	paraneoplastic	syndromes	[5].	However,	
if	RCC	becomes	symptomatic,	 it	has	often	reached	a	more	advanced	stage	with	a	
poorer	prognosis	 [9].	Haematogenous	metastatic	 spread	 is	 common	and	 in	 some	
cases	 already	 present	 at	 an	 early	 stage	 of	 disease	 [5].	 Apart	 from	 tumour	 stage,	
important	 prognostic	 factors	 include	 Fuhrman	 grade,	 RCC	 subtype,	 sarcomatoid	
features,	clinical	and	molecular	factors	[10].	The	five-year	overall	survival	rate	for	all	
types	of	RCC	is	currently	49%	[11].	
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1.1.2	TNM	classification	[6]	
	
TX	
T0	
T1	
T1a	
T1b	
T2	
T3	
	
T3a	
	
T3b	
	
T3c	
T4	
	
NX	
N0	
N1	
N2	
	
MX	
M0	
M1	
Primary	tumour	cannot	be	assessed	
No	evidence	of	primary	tumour	
Tumour	7	cm	or	less	in	greatest	dimension,	limited	to	the	kidney	
Tumour	4	cm	or	less	
Tumour	more	than	4	cm	but	not	more	than	7	cm	
Tumour	more	than	7	cm	in	greatest	dimension,	limited	to	the	kidney	
Tumour	extends	into	major	veins	or	directly	invades	adrenal	gland	
or	perinephric	tissues	but	not	beyond	Gerota	fascia	
Tumour	directly	invades	adrenal	gland	or	perinephric	tissues	but	
not	beyond	Gerota	fascia	
Tumour	grossly	extends	into	renal	vein(s)	or	vena	cava	or	its	wall	
below	diaphragm	
Tumour	grossly	extends	into	vena	cava	or	its	wall	above	diaphragm	
Tumour	directly	invades	beyond	Gerota	fascia	
	
Regional	lymph	nodes	cannot	be	assessed	
No	regional	lymph	node	metastasis	
Metastasis	in	a	single	regional	lymph	node	
Metastasis	in	more	than	one	regional	lymph	node	
	
Distant	metastasis	cannot	be	assessed	
No	distant	metastasis	
Distant	metastasis	
	
1.1.3	Stage	grouping	
	
Stage	I	
Stage	II	
Stage	III	
	
Stage	IV		
	
	
	
	
T1	
T2	
T3	
T1,	T2,	T3	
T4	
any	T	
any	T	
	
	
	
N0	
N0	
N0	
N1	
N0,	N1	
N2	
any	N	
	
	
	
M0	
M0	
M0	
M0	
M0	
M0	
M1	
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1.2	Imaging	in	renal	masses	
	
For	 treatment	 planning	 an	 accurate	 diagnosis	 is	 essential.	 The	majority	 of	 renal	
tumours	is	found	incidentally	when	imaging	is	done	for	other	medical	reasons	[3].	
The	most	commonly	used	imaging	techniques	to	then	assess	these	incidental	renal	
masses	are	ultrasound,	CT	and	MRI	[10].	In	most	cases	an	accurate	characterisation	
of	renal	tumours	is	possible	just	by	imaging	[10].	Nevertheless,	there	are	a	number	
of	 factors	 that	 can	 hamper	 a	 reliable	 diagnosis.	 With	 the	 growing	 number	 of	
incidentally	detected	RCC,	also	the	amount	of	unexpected	benign	renal	masses	at	
resection	has	 increased	 [12].	Not	 only	 technical	 factors,	 but	 also	 errors	 in	 image	
interpretation	as	well	as	certain	pathologic	features	can	lead	to	misdiagnosis	and	in	
some	cases	even	unnecessary	surgery	[13].		
	
1.3	Aims	of	the	review	
	
The	 aim	 of	 this	 review	 is	 to	 assess	 the	 diagnostic	 performance	 of	 conventional	
contrast-enhanced	CT	in	comparison	to	other	imaging	modalities	for	diagnosing	and	
staging	RCC	in	adults.	To	this	end,	we	systematically	searched	electronic	databases	
for	studies	examining	different	 imaging	modalities	 in	the	characterisation	of	renal	
masses	and	then	evaluated	the	eligible	studies.	
To	 our	 knowledge,	 no	 systematic	 review	 on	 this	 subject	 has	 been	 done	 so	 far	
although	there	is	a	great	need	for	an	overview	and	an	evaluation	of	the	numerous	
studies	that	have	looked	into	the	imaging	of	renal	masses.	
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2.	Methods	
	
2.1	Principles	of	systematic	reviews	
	
Systematic	 reviews	 and	meta-analyses	 have	 become	 essential	 in	 evidence-based	
medicine.	Their	purpose	is	not	only	to	give	a	comprehensive	and	structured	overview	
of	the	current	research	findings	in	a	certain	field.	In	many	cases	they	are	also	used	
as	a	starting	point	for	clinical	guidelines	or	as	an	identification	of	gaps	in	knowledge	
and	the	need	for	further	research	[14].	In	contrast	to	traditional	reviews,	systematic	
reviews	and	meta-analyses	are	objective,	rigorous,	transparent	and	reproducible.		
For	 conducting	 a	 systematic	 review,	 a	 precise	 research	 question	 and	 a	 search	
strategy	need	to	be	defined	in	the	beginning.	Then,	a	literature	search	is	conducted	
through	different	electronic	databases.	The	abstracts	emerging	from	the	literature	
search	are	screened	according	to	a	pre-specified	study	screening	form.	Afterwards,	
the	selected	studies	are	retrieved	as	full-text	papers	and	screened	again,	applying	
inclusion	and	exclusion	criteria.	Relevant	data	 is	extracted	 from	the	 included	 full-
texts	into	a	data	abstraction	table	and	methodological	quality	is	assessed.	If	a	meta-
analysis	is	possible,	the	results	from	two	or	more	studies	are	combined	using	specific	
statistical	 techniques	[15].	Finally,	 the	data	 is	evaluated	and	presented	within	the	
framework	of	a	systematic	review	or,	if	possible,	a	meta-analysis.	
The	review	we	performed	was	a	systematic	review	on	diagnostic	test	accuracy	(DTA),	
which	differs	from	the	more	common	reviews	or	meta-analyses	on	interventions	or	
therapies.	The	statistical	part	of	these	reviews	tends	to	be	more	challenging,	as	there	
is	usually	a	pair	of	outcomes	 (such	as	sensitivity	and	specificity)	 that	needs	 to	be	
analysed,	instead	of	a	single	outcome	[15].	Heterogeneity	of	results	is	very	common,	
making	meta-analysis	impossible	in	many	cases	[15].	However,	for	DTA	reviews,	it	is	
possible	to	address	different	questions	and	comparisons	in	the	same	article	[15].	The	
instrument	 recommended	 by	 the	 Cochrane	 collaboration	 for	 assessing	
methodological	quality	in	DTA	reviews	is	the	QUADAS-2	tool	[16].	
There	 are	 a	 number	 of	 different	 guidelines	 and	 manuals	 for	 the	 realisation	 of	
systematic	reviews	and	meta-analyses.	Our	systematic	review	was	implemented	in	
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accordance	with	the	Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-
Analyses	 (PRISMA)	 [14]	and	the	Cochrane	Handbook	for	Diagnostic	Test	Accuracy	
Reviews.		
	
2.2	Search	strategy		
	
A	comprehensive	literature	search	was	conducted	through	the	electronic	databases	
Medline,	Medline	 In-Process,	 Embase,	 The	 Cochrane	 Library,	 Latin	 American	 and	
Caribbean	Health	Sciences	(LILACS),	Web	of	Science	as	well	as	through	conference	
proceedings	 (2012	 and	 2013	 ASCO	 Annual	 Meeting).	 The	 search	 strategy	 for	
Medline,	 Medline	 In-Process	 and	 Embase	 can	 be	 seen	 below.	 Search	 items	
comprised	“renal	cell	carcinoma”	and	related	terms	as	the	target	condition,	imaging	
modalities	 and	 outcomes	 specified	 in	 our	 study	 screening	 form	 and	 appropriate	
types	of	studies.	The	search	was	limited	to	articles	published	from	1st	January	2000	
to	31st	March	2016.	No	language	restrictions	were	applied.		
	
	
	
	
1. Carcinoma,	Renal	Cell/	use	prmz	
2. kidney	carcinoma/	use	oemezd	
3. ((kidney	or	renal)	adj2	(cancer*	or	carcinoma*	or	neoplasm*	or	tum?or*	or	mass*)).tw.	
4. or/1-3	
5. *multidetector	computed	tomography/	use	prmz	
6. *nuclear	magnetic	resonance	imaging/	or	diffusion	tensor	imaging/	or	echo	planar	imaging/	
or	functional	magnetic	resonance	imaging/	or	interventional	magnetic	resonance	imaging/	
7. echography/	use	oemezd	
8. exp	*computer	assisted	tomography/	use	oemezd	
9. exp	*tomography,	emission-computed/	use	prmz	
10. *urography/	use	prmz	
11. *intravenous	urography/	use	oemezd	
12. *magnetic	resonance	imaging/	
2.2.1	Search	strategy	for	Medline,	Medline	In-Process	and	Embase	
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13. (MDCT	 or	 CECT	 or	 CT-PET	 or	 magnetic	 resonance	 imaging	 or	 MRI	 or	 ultrasound	 or	
ultrasonography	 or	 computed	 tomography	 or	 CT-positron	 emission	 tomography	 or	
urography).tw.	
14. or/5-13	
15. "sensitivity	and	specificity"/	
16. roc	curve/	
17. receiver	operating	characteristic/	use	oemezd	
18. predictive	value	of	tests/	
19. diagnostic	errors/	use	oemezd	
20. false	positive	reactions/	use	prmz	
21. false	negative	reactions/	use	prmz	
22. diagnostic	accuracy/	use	oemezd	
23. diagnostic	value/	use	oemezd	
24. du.fs.	use	prmz	
25. sensitivity.tw.	
26. distinguish$.tw.	
27. differentiat$.tw.	
28. identif$.tw.	
29. detect$.tw.	
30. diagnos$.tw.	
31. (predictive	adj4	value$).tw.	
32. accura$.tw.	
33. or/15-32	
34. comparative	study/	use	prmz	
35. follow-up	studies/	use	prmz	
36. time	factors/	use	prmz	
37. Treatment	outcome/	use	oemezd	
38. major	clinical	study/	use	oemezd	
39. controlled	study/	use	oemezd	
40. (preoperat$	or	pre	operat$).tw.	
41. (prospective$	or	retrospective$).tw.	
42. (cohort$	or	case	series).tw.	
43. (compare$	or	compara$).tw.	
44. case	report/	use	oemezd	
45. case	reports.pt.	
46. exp	clinical	trial/	
47. randomized	controlled	trial.pt.	
48. controlled	clinical	trial.pt.	
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49. randomization/	use	oemezd	
50. randomi?ed.ab.	
51. randomly.ab.	
52. trial.ab.	
53. groups.ab.	
54. or/34-53	
55. 4	and	14	and	33	and	54	
56. Carcinoma,	Renal	Cell/di	[Diagnosis]	
57. kidney	carcinoma/di	[Diagnosis]	
58. 14	and	(56	or	57)	
59. 55	or	58	
60. exp	animals/	not	humans/	
61. (letter	or	editorial	or	comment*	or	review	or	note).pt.	
62. 59	not	(60	or	61)	
63. limit	62	to	yr="2000	-Current"	
	
2.3	Study	selection	
	
All	titles	and	abstracts	matching	the	search	items	were	screened	by	two	independent	
reviewers.	Screening	was	done	according	to	a	pre-specified	study	screening	form.	
The	 selected	 abstracts	 were	 then	 retrieved	 as	 full	 texts	 and	 screened	 again	
independently	by	the	two	reviewers.		
For	inclusion,	the	following	pre-defined	inclusion	criteria	had	to	be	fulfilled:	
• The	target	condition	had	to	be	RCC	
• The	studies	were	required	to	report	at	least	sensitivity	and	specificity	data		
• The	reference	standard	had	to	be	pathological	confirmation	for	test-positives	
and	either	pathology	or	CT/MRI	follow-up	for	test-negatives	
• Possible	comparator	tests	were:		
o (Dynamic)	contrast-enhanced	computed	tomography	(CECT)	
o Non-contrast	CT	
o Multidetector	CT	
o Ultrasonography	
o Contrast-enhanced	ultrasound	(CEUS)	
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o Doppler	ultrasound	
o Intravenous	urography	
o Plain	MRI	
o Contrast-enhanced	MRI	
o Diffusion-weighted	MRI	
o Positron	emission	tomography	(PET)	
o PET/CT	
	
Furthermore,	the	following	exclusion	criteria	were	applied:	
• Case	reports	with	<	10	patients	
• Studies	with	patients	under	18	years	of	age		
• Studies	with	<	1	year	of	follow-up	
	
Other	reasons	for	exclusion	were	irrelevant	outcome	data,	the	lack	of	data	for	the	
target	 condition,	 incomplete	 data,	 inadequate	 reference	 standard,	 reviews,	
comments	 and	 meta-analyses.	 Disagreement	 between	 the	 two	 reviewers	 was	
resolved	by	consensus	or	by	consulting	a	third	person.	
	
2.4	Data	abstraction	and	risk	of	bias	assessment	
	
Following	full	text	screening,	data	from	the	selected	studies	was	extracted	into	an	
appropriate	 data	 abstraction	 form.	 Information	 was	 collected	 about	 the	 study	
design,	 aims	 and	 conclusions	 of	 the	 study,	 patient	 and	 tumour	 characteristics,	
reference	standard,	interventions	and	outcome	measures.		
Subsequently,	the	risk	of	bias	for	each	study	was	assessed	using	the	QUADAS-2	tool	
[16].	 This	 tool	 consists	 of	 four	 domains:	 patient	 selection,	 index	 test,	 reference	
standard	and	flow	and	timing.	A	summary	of	the	risk	of	bias	assessment	can	be	found	
in	figure	1.	
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Figure	1:	Risk	of	bias	assessment	
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2.5	Outcome	measures	and	synthesis	
	
The	 primary	 outcome	 measures	 assessed	 were	 accuracy,	 sensitivity,	 specificity,	
positive	and	negative	predictive	value	 (PPV/NPV)	 for	diagnosing	and	staging	RCC.	
Whenever	 possible,	 data	 was	 pooled	 and	 median	 sensitivity/specificity	 was	
calculated.	 Information	 was	 summarised	 by	 imaging	 modality	 and	 by	 similar	
populations	 examined	 (subgroup	 analysis).	 The	 subgroup	 analysis	 of	 small	 renal	
masses	≤	4	cm	(SRM)	was	pre-specified.		
Based	on	the	heterogeneity	of	data,	a	narrative	synthesis	had	to	be	chosen	over	a	
quantitative	analysis.	
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3.	Findings	
	
3.1	Study	selection	
	
Through	 database	 searching,	 4593	 abstracts	 matching	 our	 search	 items	 were	
identified.	Out	of	these,	182	abstracts	were	selected	for	full	text	screening.		As	six	
articles	were	not	possible	to	be	retrieved,	we	ended	up	with	176	papers	for	full	text	
screening.	 In	 total,	 40	 studies	 comprising	 4354	 patients	 were	 eligible	 for	 data	
abstraction	and	analysis.	
Out	of	the	40	included	studies,	22	were	case	series	investigating	only	one	imaging	
modality,	 while	 18	 were	 comparative	 studies,	 examining	 two	 or	 more	 different	
imaging	 techniques.	 30	 papers	 reported	 on	 trials	 examining	 diagnostic	 accuracy,	
while	nine	studies	examined	staging	accuracy	and	one	trial	rated	both	diagnostic	and	
staging	accuracy.	All	of	them	were	retrospective.	
A	flow	chart	displaying	the	process	of	study	selection	can	be	seen	in	figure	2.	
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Figure	2:	Study	selection	
3.2	Imaging	
	
Overall,	 four	 major	 imaging	 modalities	 and	 their	 numerous	 variations	 were	
investigated	in	the	40	studies:	CT,	MRI,	PET/CT	and	ultrasound.	Contrast-enhanced	
CT	as	the	traditional	gold	standard	[17]	for	diagnosing	renal	cell	cancer	was	studied	
in	23	articles.	MRI	was	examined	in	twelve	papers,	using	various	different	techniques	
such	 as	 diffusion-weighted,	 contrast-enhanced	 or	 blood	 oxygen	 level-dependent	
MRI.	 	Ultrasound	was	also	used	 in	twelve	studies,	 including	CEUS,	colour	Doppler	
ultrasound	and	unenhanced	conventional	sonography.	PET-CT	was	examined	in	four	
articles,	using	different	tracers	such	as	18F-FDG	or	124I-girentuximab.	
Tables	1	and	2	give	a	summary	of	the	characteristics	of	the	included	studies.	
4593	abstracts	and	titles	identified	through	database	searching
182	articles	selected	for	full	text	screening
176	full	text	articles	retrieved 6	articles	not	possible	to	retrieve
176	full	text	articles	screened
40	studies	included
136	studies	excluded
Reasons:	case	reports	including	
<	10	patients,	studies	with	
patients	<18	years	of	age,	
studies	with	<	1	year	of	follow-
up,	lack	of	sensitivity	or	
specificity	data,	irrelevant	or	
incomplete	outcome	data
9 studies	assessing	
staging	accuracy
30	studies	assessing	
diagnostic	accuracy
1	study	assessing	both	
diagnostic	and	staging	
accuracy
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Table	1:	Characteristics	of	included	studies	assessing	diagnostic	accuracy	
	
Study	 No.	
of	
pts.	
Tumour	
size	(cm)	
(mean)	
Tumour	
subtypes	
Reference	
standard	
Intervention	 Outcome:	
Diagnostic	
accuracy	
Ak	2005	 19	 7.42±0.5
7	
15	RCC	
2	AML	
2	others	
histo-
pathology	
18F-FDG	
PET/CT	
Sensitivity:	86%	
Specificity:	75%	
Chen	
2015	
99	 1.81	±	
0.59	(all	
≤	3)	
81	RCC	
21	AML	
histo-
pathology	
CEUS	
	
	
Conven-
tional	
ultrasound	
Sensitivity:	89%	
Specificity:	81%	
	
Sensitivity:	56%	
Specificity:	71%	
Choi	
2012	
84	 RCC:	2.74	
±0.65	
benign:	
2.41	
±0.73	
(all	≤	4)	
67	RCC	
6	AML	
8	onco-
cytomas	
2	adenomas	
1	cyst	
histo-
pathology	
Quadriphasic	
multidetec-
tor	helical	CT	
Sensitivity:	94%	
Specificity:	41%	
Divgi	
2013	
195	 NR	 168	RCC	
4	AML	
16	onco-
cytomas	
1	adenoma	
2	cysts	
3	others	
histo-
pathology	
124I-giren-
tuximab	
PET/CT	
	
Multiphasic	
CECT	
Sensitivity:	86%	
Specificity:	86%	
	
	
Sensitivity:	76%	
Specificity:	47%	
Hindman	
2012	
108	 RCC:	5.6		
AML:	2.1	
88	RCC	
20	AML	
histo-
pathology	
MRI		 Sensitivity:	89%	
Specificity:	65%	
Ho	2012	 58	 RCC:	
4.8±3.5	
AML:	
3.3±1.7	
50	RCC	
16	AML	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
Dual	tracer	
PET/CT	
Sensitivity:	90%	
Specificity:	90%	
Ignee	
2010	
143	 RCC:	
5.4±3.1	
AML	
3.9±1.4	
109	RCC	
4	AML	
1	onco-
cytoma	
1	adenoma	
17	non-RCC	
malignant	
tumours	
14	others	
histo-
pathology	
CEUS	
	
Sensitivity:	97%	
Specificity:	45%	
Jiang	
2008	
26	 4.3	
(range	
2.2-15.3)	
15	RCC	
11	cysts	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
CEUS	
	
	
	
PDUS	
	
	
CECT	
Sensitivity:	
100%	
Specificity:	64%	
	
Sensitivity:	47%	
Specificity:	55%	
	
Sensitivity:	67%	
Specificity:	67%	
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Kim	2002	 110	 5.7±2.5	 110	RCC:		
76	ccRCC		
34	non-ccRCC	
histo-
pathology	
CECT	 Sensitivity:	
74%/84%	
Specificity:	
100%/91%	
Kim	2009	 41	 3.9	 26	RCC	
38	cysts	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
DW	MR	
	
	
CE	MR	
Sensitivity:	71%	
Specificity:	91%	
	
Sensitivity:	65%	
Specificity:	96%	
Kim	2012	 60	 ccRCC:	
2.81	
±0.74	
non-
ccRCC:	
2.18	
±0.75	
(all	≤	4)	
60	RCC:		
42	ccRCC	
18	non-ccRCC	
histo-
pathology	
DCE	MR	 Sensitivity:	
81%/76%	
Specificity:	
88%/100%	
Kim	2016	 552	 ccRCC:	
2.8		
pRCC:	3.1	
chRCC:	
3.3		
AML:	2.6	
(all	≤	4)	
512	RCC	
51	AML	
histo-
pathology	
Three-phase	
MDCT	
	
	
Sensitivity:	85%	
Specificity:	84%	
(ccRCC	vs.	AML)	
Sensitivity:	88%	
Specificity:	92%	
(ccRCC	vs.	pRCC)	
Sensitivity:	74%	
Specificity:	79%	
(ccRCC	vs.	
chRCC)	
Kutman	
2013	
149	 4.8±2.7	 127	RCC	
8	AML	
14	onco-
cytomas	
histo-
pathology	
DCE	CT	 Sensitivity:	88%	
Specificity:	87%	
Li	2011	 72	 all	≤4	
(range	1-
4)	
58	RCC	
12	AML	
2	onco-
cytomas	
histo-
pathology	
CEUS	
	
CECT	
Sensitivity:	93%	
Specificity:	71%	
Sensitivity:	81%		
Specificity:	64%		
Li	2013	 91	 3.3±1.7		 85	RCC	
13	AML	
2	onco-
cytomas	
histo-
pathology	
CEUS	
	
Conven-
tional	
ultrasound	
Sensitivity:	93%	
Specificity:	97%	
Sensitivity:	60%	
Specificity:	73%	
Lu	2015	 192	 ccRCC:	
3.7	±	1.8	
pRCC:	3.5	
±	1.1	
chRCC:	
2.9	±	0.9		
AML:	4.1	
±	1.4	
159	RCC	
34	AML	
histo-
pathology	
CEUS	 Sensitivity	1:	
96%	
Specificity	1:	
95%	
(ccRCC	vs.	
pRCC/	chRCC)	
Sensitivity	2:	
90%	
Specificity	2:	
96%	(RCC	vs.	
AML)	
Notoha-
miprodjo	
2013	
18	 ccRCC:		
5.6	±2.5	
pRCC:	
4.1±1.4	
18	RCC:	
14	ccRCC	
4	pRCC	
histo-
pathology	
DW	MRI	
	
	
	
Sensitivity:	
100%	
Specificity:	50%	
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BOLD	MRI	
	
	
	
DCE	MRI	
Sensitivity:	
100%	
Specificity:	33%	
	
Sensitivity:	
100%	
Specificity:	75%	
Pedrosa	
2008	
76	 5.4	
(range	
1.1–15)		
69	RCC:		
48	ccRCC	
15	pRCC	
5	chRCC	
1	unclassified	
RCC	
10	others	
histo-
pathology	
MRI	 Sensitivity:	
92%/80%	
Specificity:	
83%/94%	
Quaia	
2008	
40	 4.3±2.2	 21		RCC	
18	cysts	
1	cystic	
nephroma	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
CEUS	
	
	
Unenhanced	
sonography	
	
Multiphasic	
CECT	
Sensitivity:	89%	
Specificity:	74%	
	
Sensitivity:	46%	
Specificity:	12%	
	
Sensitivity:	86%	
Specificity:	51%	
Ruppert-
Kohlmayr	
2004	
97	 ccRCC:	
5.9±4.8		
pRCC:	
2.5±1.1	
(range	
1.1–31)	
NR	(>107)	
RCC	
histo-
pathology	
Triphasic	
CECT	
Sensitivity:	
98%/95%/95%/
92%	
Specificity:	
92%/92%/75%/
69%	
Sasiwi-
monphan	
2012	
75	 AML:	2.1	
RCC:	2.4	
(all	≤	4)	
71	RCC	
10	AML	
histo-
pathology	
MRI	 Sensitivity:	73%	
Specificity:	99%	
Shebel	
2011	
97	 NR	
(range	2-
8)	
79	RCC	
4	AML	
14	
oncocytomas	
histo-
pathology	
Quadriphasic	
multidetec-
tor	CT		
Sensitivity:	
98%/92%	
Specificity:	
90%/90%	
Song	
2009	
104	 NR	 56	RCC	
48	cysts	
histo-
pathology	
Multiphasic	
CECT	
Sensitivity:	97%	
Specificity:	86%	
Sun	2009	 112	 5.4	
(range	
1.1-19.5)	
113	RCC:	
75	ccRCC	
28	pRCC	
10	chRCC	
histo-
pathology	
DCE	MRI	 Sensitivity:	93%	
Specificity:	96%	
Tamai	
2005	
29	 5.1±2.1	 24	RCC	
1	collecting	
duct	
carcinoma	
1	urothelial	
carcinoma	
1	AML	
2	onco-
cytomas	
histo-
pathology	
CEUS	
	
	
CECT	
Sensitivity:	94%	
Specificity:	46%	
	
Sensitivity:	89%	
Specificity:	73%	
Taouli	
2009	
64	 4.2±2.5	
(range	
1.0–12.7)	
28	RCC	
62	cysts	
10	AML	
6	onco-
cytomas	
3	others	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
DW	MRI	
	
	
CE	MRI	
	
	
Sensitivity:	86%	
Specificity:	80%	
	
Sensitivity:	
100%	
Specificity:	89%	
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CE	MRI	+	
ADC	
information	
from	DW	MR	
Sensitivity:	NR	
Specificity:	96%	
Xu	2010	 109	 RCC	4.2	
AML	3.7	
(range	
1.5–11.7)	
93	RCC	
33	AML	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
CEUS	 Sensitivity:	88%	
Specificity:	97%	
Xue	2015	 201	 ccRCC:	
3.64	±	
1.96	
pRCC:	
3.65	±	
2.04	
205	RCC	 histo-
pathology	
CEUS	 Sensitivity:	53%	
Specificity:	97%	
(for	prediction	
of	pRCC)	
Young	
2013	
274	 4.2	
(range	
0.7–18.7)	
249	RCC	
49	onco-
cytomas	
histo-
pathology	
Quadri-
phasic	
multide-
tector	CT	
Sensitivity:		
86%/94%/92%	
Specificity:	
43%/62%/25%	
Yuan	
2011	
87	 3.2±2.4	
(range	
1.2-12)	
73	RCC	
14	AML	
histo-
pathology	
and/or	
follow-up	for	
test-
negatives	
CEUS	
	
	
CECT		
Sensitivity:	96%		
Specificity:	57%	
	
Sensitivity:	78%		
Specificity:	50%	
Zhang	
2012	
30	 NR	 24	RCC	
1	neuro-
endocrine	
tumour	
3	renal	
lymphomas	
2	others	
histo-
pathology	
18F-FDG	
PET/CT	
Sensitivity:	90%		
Specificity:	
100%		
	
Table	2:	Characteristics	of	included	studies	assessing	staging	accuracy	 	
	
Study	 No.	
of	
pts.	
Tumour	
size	
Tumour	
subtypes	
Reference	
standard	
Endpoint	
examined	
Inter-
vention	
Outcome:	
Staging	
accuracy	
Hall-
scheidt	
2004	
58	 NR	 82	RCC	
1	AML	
1	onco-
cytoma	
1	cystic	
nephroma	
4	urothe-
lial	
carcinomas	
histo-
pathology	
general	
staging	
MRI	
	
	
	
	
Triphasic	
multi-
detector	
CT	
Sensitivity:	
91%/89%	
Specificity:	
83%/67%	
	
Sensitivity:	
88%/86%	
Specificity:	
72%/77%	
Hall-
scheidt	
2005	
23	 NR	 23	RCC	 histo-
pathology	
tumour	
thrombus	
MRI	
	
	
	
	
Triphasic	
multi-
Sensitivity:	
100%/85%	
Specificity:	
75%	
	
Sensitivity:	
93%	
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detector	
CT	
Specificity:	
80%	
Hedgire	
2013	
109	 4.5	
(median)	
(range	
0.8-16.7)	
109	RCC	
	
histo-
pathology	
peri-
nephric	fat	
invasion	
MRI	
	
	
	
	
Quadri-
phasic	
CECT	
Sensitivity:	
72%	
Specificity:	
93%	
	
Sensitivity:	
84%	
Specificity:	
56%	
Ignee	
2010	
143	 RCC:	
5.4±3.1	
AML	
3.9±1.4	
109	RCC	
4	AML	
1	onco-
cytoma	
1	adenoma	
17	non-
RCC	malig-
nant	
tumours	
14	others	
histo-
pathology	
renal	vein	
invasion	
CEUS	
	
	
	
	
CECT	
Sensitivity:	
83%	
Specificity:	
96%	
	
Sensitivity:	
42%	
Specificity:	
98%	
Karlo	
2013a	
186	 5.3	
(range	
1.3–
23.0)	
188	RCC	
	
histo-
pathology	
muscular	
venous	
branch	
invasion	
	
renal	sinus	
fat	
invasion	
MRI	 Sensitivity:	
100%	
Specificity:	
42%	
	
Sensitivity:	
100%	
Specificity:	
94%	
Karlo	
2013b	
261	 3.8	
(range	
0.6–
19.3)	
258	RCC	
3	non-RCC	
malignant	
tumours	
histo-
pathology	
collecting	
system	
invasion	
Triphasic	
CECT	
Sensitivity:	
100%	
Specificity:	
100%	
Karlo	
2013c	
115	 4.2	
(range	
0.9–
13.4)	
103	RCC	
6	onco-
cytomas	
2	others	
histo-
pathology	
muscular	
venous	
branch	
invasion	
Mono-
phasic	
CECT	
Sensitivity:	
94%	
Specificity:	
30%	
	
Khan	
2008	
30	 NR	 30	RCC	 histo-
pathology	
tumour	
thrombus	
Colour	
Doppler	
ultrasound	
	
	
CECT	
Sensitivity:	
92%	
Specificity:	
94%	
	
Sensitivity:	
62%	
Specificity:	
82%	
Sokhi	
2015	
117	 median	
5.5	
(range	
0.9–19)		
117	RCC	 histo-
pathology	
renal	sinus	
fat	
invasion	
	
	
peri-
nephric	fat	
invasion	
Biphasic	
CECT	
Sensitivity:	
71%/88%	
Specificity:	
79%/71%	
	
Sensitivity:	
83%/68%	
Specificity:	
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renal	vein	
invasion	
76%/72%	
	
Sensitivity:	
59%/69%	
Specificity:	
93%/91%	
Tsili	
2013	
47	 5.1	
(range	
1.2-15)	
48	RCC	 histo-
pathology	
peri-
nephric	fat	
invasion	
	
	
renal	sinus	
fat	
invasion	
Quadri-
phasic	
multi-
detector	
CT	
Sensitivity:	
69%	
Specificity:	
71%	
	
Sensitivity:	
97%	
Specificity:	
43%	
	
	
	
Twenty-three	studies	investigated	the	performance	of	contrast-enhanced	CT	(CECT)	
in	the	characterisation	of	renal	masses.		
As	anticipated,	diagnostic	and	staging	accuracy	values	were	very	good,	but	in	several	
cases	they	were	exceeded	by	the	values	that	other	imaging	modalities	attained.	
Overall,	CECT	displayed	a	very	good	median	diagnostic	sensitivity	of	88%	(IQR	81-
94%)	and	a	specificity	of	75%	(IQR	51-90%).	
Twelve	papers	analysed	the	performance	of	CECT	in	the	differentiation	of	RCC	from	
other	renal	tumours	[18-29].	
Five	of	them	[20,	23,	24,	27,	29]	compared	the	diagnostic	accuracy	of	CECT	to	that	
of	CEUS	and	other	ultrasound	techniques.	All	of	these	revealed	a	superiority	of	CEUS	
in	 the	 characterisation	 of	 renal	 tumours.	 While	 CECT	 only	 reached	 a	 median	
sensitivity	of	81%	(IQR	72.5-87.5%)	in	these	studies,	CEUS	was	able	to	achieve	94%	
(IQR	91-98%).	Regarding	specificity	though,	values	were	equally	poor	with	a	median	
of	 64%	 for	 both	 imaging	modalities	 (IQR	 50.5-70%	 for	 CECT	 and	 51.5-72.5%	 for	
CEUS).	
In	 comparison	 to	 power	 Doppler	 ultrasound	 [20]	 and	 conventional	 unenhanced	
sonography	[24],	CECT	was	superior	though.	
One	multi-centre	study	[19]	compared	the	diagnostic	accuracy	of	contrast-enhanced	
CT	to	that	of	124I-girentuximab	PET/CT.	Analysing	a	 large	variety	of	different	renal	
lesions	 in	a	 large	number	of	patients,	CECT	only	reached	a	sensitivity	of	76%	and	
3.2.1	Contrast-enhanced	CT	
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specificity	of	47%,	while	PET/CT	achieved	values	of	86%	and	86%.		
Three	studies	 [18,	21,	23]	only	 included	renal	masses	≤	4	cm	 in	 their	analysis.	All	
three	 studies	 displayed	 high	 sensitivity	 with	 a	 median	 of	 85%	 (range	 81-94%)	
combined	with	a	mediocre	median	specificity	of	64%	(range	41-84%).	
Another	 four	studies	 [20,	24,	26,	30]	analysed	the	diagnostic	accuracy	of	CECT	 in	
complex	cystic	renal	masses.	The	results	were	rather	heterogeneous,	with	sensitivity	
values	ranging	from	67%	[20]	to	97%	[26]	and	a	median	of	86%.	In	comparison	to	
the	performance	of	CEUS	[20,	24,	30],	CECT	was	inferior.		
Finally,	 five	 studies	 [21,	 25,	 28,	 31,	 32]	 analysed	 the	 performance	 of	 CT	 in	 the	
discrimination	 of	 clear	 cell	 RCC	 (ccRCC)	 from	 other	 RCC	 subtypes.	 In	 the	
differentiation	 of	 ccRCC	 from	 papillary	 RCC	 (pRCC)	 they	 were	 able	 to	 provide	 a	
median	 sensitivity	of	94.5%	 (IQR	91-95.75%)	and	 specificity	of	83.5%	 (IQR	67.25-
92%)	[21,	28,	31,	32].	Regarding	the	discrimination	of	ccRCC	from	chromophobe	RCC	
(chRCC),	a	median	sensitivity	of	92%	and	specificity	of	79%	was	reached	[21,	25,	28].	
For	 differentiating	 ccRCC	 from	 non-ccRCC	 in	 general,	 a	 median	 sensitivity	 and	
specificity	of	79%	and	95.5%	was	attained	in	one	study	[31].	
	
Nine	 studies	 investigated	 the	 eligibility	 of	 CECT	 for	 staging	 RCC.	 In	 total,	 staging	
accuracy	was	very	good.	
General	 staging	 sensitivity	 [33]	 reached	 a	median	of	 87%	 (88%	and	86%	 for	 two	
different	readers)	and	a	median	specificity	of	74.5%	(72%/77%).	For	the	detection	of	
tumour	 thrombus	 [34,	 35],	 median	 sensitivity	 was	 77.5%	 and	 specificity	 81%.	
Compared	 to	MRI,	 accuracy	was	 inferior	 though	 in	 this	 respect	 [34].	 Concerning	
perinephric	fat	invasion	[36-38],	CECT	achieved	a	median	sensitivity	and	specificity	
of	76%	(IQR	68.25%-83.75%)	and	71.5%	(IQR	59.75%-71.5%).	For	renal	vein	invasion	
[30,	38]	sensitivity	was	poor	(median:	59%),	while	specificity	reached	a	median	of	
93%.	In	contrast,	for	muscular	venous	branch	invasion	[39],	sensitivity	was	excellent	
(94%)	while	specificity	was	very	poor	(30%).	Regarding	renal	sinus	fat	invasion	two	
studies	[37,	38]	reported	a	median	sensitivity	of	88%	and	specificity	of	71%.	In	the	
detection	of	collecting	system	invasion,	both	sensitivity	and	specificity	even	reached	
100%	in	one	study	[40].	
	
	 25	
Table	3:	CT	-	Summary	of	diagnostic	accuracy	
	
Study	 Intervention	 Sensitivity	 Specificity	
Choi	2012	 Quadriphasic	multidetector	
helical	CT	
94%	 41%	
Divgi	2013	 Multiphasic	contrast-enhanced	
CT	
76%	 47%	
Jiang	2008	 Contrast-enhanced	CT	 67%	 67%	
Kim	2002	 Contrast-enhanced	CT	 74%	
84%	
100%	
91%	
Kim	2016	 Three-phase	MDCT	
	
	
85%	
88%	
74%	
84%	
92%	
79%	
Kutman	2013	 Dynamic	contrast	enhanced	CT	 88%	 87%	
Li	2011	 Contrast-enhanced	CT	 81%	 64%	
Quaia	2008	 Multiphasic	contrast-enhanced	
CT	
86%	 51%	
Ruppert-
Kohlmayr	2004	
Triphasic	contrast-enhanced	CT	 98%	
95%	
95%	
92%	
92%	
92%	
75%	
69%	
Shebel	2011	 Quadriphasic	multidetector	CT		 98%	
92%	
90%	
90%	
Song	2009	 Multiphasic	contrast-enhanced	
CT	
97%	 86%	
Tamai	2005	 Contrast-enhanced	CT	 89%	 73%	
Young	2013	 Quadriphasic	multidetector	CT	 86%	
94%	
92%	
43%	
62%	
25%	
Yuan	2011	 Contrast-enhanced	CT		 78%	 50%	
Median	(+/-	IQR)	 88%	(81-94%)	 75%	(51-90%)	
	
	
	
Twelve	studies	investigated	the	diagnostic	and	staging	accuracy	of	MRI	for	RCC	[33,	
34,	36,	41-49].		
Various	 different	 imaging	 modes	 were	 used,	 such	 as	 diffusion-weighted	 (DW),	
dynamic	contrast-enhanced	(DCE)	and	blood	oxygen	level-dependent	(BOLD)	MRI	as	
well	 as	 a	 combination	 of	 different	 techniques.	On	 the	whole,	MRI	 had	 very	 high	
diagnostic	accuracy	values,	with	a	median	sensitivity	of	87.5%	(IQR	75.25-100%)	and	
specificity	of	89%	(IQR	75-96%).	
	
Four	 studies	 [41,	 42,	 46,	 48]	 investigated	 the	 performance	 of	 MRI	 in	 the	
3.2.2	MRI	
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discrimination	between	RCC	and	other	renal	tumours.		
Two	of	them	[41,	46]	used	MRI	to	differentiate	between	RCC	and	AML	with	minimal	
fat.	They	achieved	a	median	sensitivity	of	81%	(range	73-89%)	and	specificity	of	82%	
(range	 65-99%)	 respectively.	 The	 lower	 sensitivity	 in	 the	 second	 study	 combined	
with	the	higher	specificity	could	be	due	to	the	fact	that	only	renal	masses	≤	4	cm	
were	included.	
Another	 one	 [48]	 compared	DW	MRI,	 CE	MRI	 and	 a	 combination	 of	 both	 in	 the	
diagnosis	of	RCC.	CE	MRI	was	slightly	superior	to	DW	MRI	with	a	sensitivity	of	100%	
and	a	specificity	of	89%	(values	were	86%	and	80%	for	DW	MRI).	The	combination	
of	CE	MRI	with	the	apparent	diffusion	coefficient	(ADC)	information	from	DW	MRI	
was	able	to	increase	specificity	to	96%.		
The	last	one	of	them	[42]	compared	the	eligibility	of	ADC	measurement	in	DW	MRI	
with	that	of	contrast-enhanced	MRI	in	the	differentiation	of	T1	hyperintense	renal	
lesions.	DW	MRI	was	able	to	reach	a	sensitivity	of	71%	and	a	specificity	of	91%,	while	
CE	MRI	rendered	a	sensitivity	of	65%	and	a	specificity	of	96%.	
Another	 four	 studies	 [43-45,	 47]	 examined	 the	 ability	 to	 differentiate	 between	
different	RCC	subtypes	on	MRI.		
One	of	them	[44]	compared	the	eligibility	of	diffusion-weighted	(DW),	blood	oxygen	
level-dependent	 (BOLD)	 and	 dynamic	 contrast-enhanced	 (DCE)	 MRI	 in	 the	
differentiation	 of	 ccRCC	 from	 pRCC.	 All	 three	 modes	 were	 able	 to	 achieve	 a	
sensitivity	 of	 100%	with	 varying	 specificity	 values.	DCE	MRI	 achieved	 the	 highest	
diagnostic	accuracy	with	a	specificity	of	75%.	DW	and	BOLD	MRI	only	reached	poor	
specifities	of	50%	and	33%	respectively.	However,	the	number	of	patients	included	
in	the	study	was	very	low	with	only	18	participants.	
A	second	study	[47]	that	used	DCE	MRI	to	differentiate	ccRCC	from	pRCC	attained	
sensitivity	and	specificity	values	of	83%	and	89%.		
Similarly,	in	the	discrimination	of	ccRCC	and	non-ccRCC	in	small	renal	masses	≤4	cm	
DCE	MR	 yielded	 good	 diagnostic	 accuracy	 values	with	 a	 sensitivity	 of	 81%	 and	 a	
specificity	of	88%	[43].	
The	final	four	studies	investigated	the	usefulness	of	MRI	in	staging	RCC.		
Regarding	general	staging	of	RCC	[33],	MRI	was	able	to	achieve	an	excellent	median	
sensitivity	of	90%	(91%	and	89%	for	two	different	readers)	that	even	surpassed	that	
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of	 multidetector	 CT	 with	 87%	 (88%/86%).	 Specificity	 was	 lower	 though	 with	 a	
median	of	75%	(83%/67%).		
For	the	detection	of	perinephric	fat	invasion	[36],	MRI	reached	a	sensitivity	of	72%	
and	a	specificity	of	93%.	In	the	identification	of	renal	sinus	fat	invasion	and	muscular	
venous	branch	invasion	[49]	sensitivity	values	of	100%	were	achieved.	For	muscular	
venous	branch	invasion	specificity	was	poor	though	with	only	42%.	
	
Table	4:	MRI	-	Summary	of	diagnostic	accuracy	
	
Study	 Intervention	 Sensitivity	 Specificity	
Hindman	2012	 MRI	(standard	techniques)	 89%	 65%	
Kim	2009	 Diffusion-weighted	MR	
Contrast-enhanced	MR	
71%	
65%	
91%	
96%	
Kim	2012	
Dynamic	contrast-enhanced	MR	 81%	
76%	
88%	
100%	
Notohamiprodjo	
2013	
Diffusion-weighted	MRI	
Blood	oxygen	level-dependent	
MRI	(BOLD)	
Dynamic	contrast-enhanced	MRI	
100%	
100%	
	
100%	
50%	
33%	
	
75%	
Pedrosa	2008	 MRI	 92%	
80%	
83%	
94%	
Sasiwimonphan	2012	 MRI	 73%	 99%	
Sun	2009	 Dynamic	contrast-enhanced	MRI	 93%	 96%	
Taouli	2009	
Diffusion-weighted	MRI	
Contrast-enhanced	MRI	
CE	MRI	+	ADC	information	from	
DW	MR	
86%	
100%	
NR	
80%	
89%	
96%	
Median	(+/-	IQR)	 87.5%	
(75.25-
100%)	
89%	(75-
96%)	
	
	
	
3.2.3.1	Unenhanced	sonography	
	
Three	 studies	 [24,	 50,	 51]	 compared	 the	 diagnostic	 value	 of	 unenhanced	
conventional	 ultrasound	 to	 CEUS	 and/or	 CECT.	 	 All	 of	 them	 reported	 very	 poor	
diagnostic	accuracy	values	for	the	diagnosis	of	RCC	with	a	median	sensitivity	of	56%	
(range	46-60%)	and	specificity	of	71%	(range	12-73%).	Especially	in	the	diagnosis	of	
malignancy	 in	 complex	 renal	 cysts,	 sensitivity	 and	 specificity	 of	 unenhanced	
3.2.3	Ultrasound	
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sonography	were	extremely	poor	(46%	and	12%)	[24].	 In	differentiating	RCC	from	
AML	 and	 oncocytoma,	 diagnostic	 accuracy	 was	 slightly	 better	 with	 a	 median	
sensitivity	 of	 58%	 and	 specificity	 of	 72%,	 but	 still	 far	 from	 the	 values	 that	 were	
reached	with	CEUS	and	CECT	[50,	51].	
	
Table	5:	Unenhanced	sonography	-	Summary	of	diagnostic	accuracy	
	
Study	 Intervention	 Sensitivity	 Specificity	
Chen	2015	 Unenhanced	sonography	 56%	 71%	
Li	2013	 Unenhanced	sonography	 60%	 73%	
Quaia	20008	 Unenhanced	sonography	 46%	 12%	
Median	 56%	 71%	
	
3.2.3.2	Colour	Doppler	ultrasound	
	
One	paper	[20]	compared	the	accuracy	of	power	Doppler	ultrasound	to	that	of	CEUS	
and	CECT	in	differentiating	complex	renal	cysts	from	cystic	RCC.	Both	sensitivity	and	
specificity	were	rather	poor	with	values	of	47%	and	55%	and	were	not	able	to	keep	
up	with	the	values	achieved	by	the	other	imaging	modalities.		
Another	article	[35]	examined	the	value	of	conventional	colour	Doppler	in	detecting	
venous	tumour	thrombus	in	RCC.	For	this	indication,	colour	Doppler	appeared	to	be	
a	very	useful	tool	with	excellent	sensitivity	and	specificity	of	96%	and	95%	that	even	
exceeded	values	reached	by	CECT.		
Both	 studies	 had	 rather	 small	 sample	 sizes	 though	with	 only	 26	 and	 30	 patients	
respectively.		
	
3.2.3.3	Contrast-enhanced	ultrasound	(CEUS)	
	
The	value	of	CEUS	in	the	characterisation	of	renal	masses	was	examined	in	eleven	
studies	[20,	23,	24,	27,	29,	30,	50-54].	
All	 in	 all,	 CEUS	 was	 able	 to	 achieve	 excellent	 sensitivity	 values	 combined	 with	
mediocre	specificity.	Specificity	values	were	rather	heterogeneous	with	a	median	of	
72.5%	 (IQR	 54-97%).	 In	 contrast,	 median	 sensitivity	 reached	 93%	 (IQR	 88.75-
98.25%).	
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Three	studies	[20,	24,	30]	found	CEUS	to	be	superior	to	CECT	also	in	the	subgroup	of	
complex	cystic	renal	masses	with	a	median	sensitivity	of	94.5%	and	specificity	of	69%	
(CT:	86%	and	67%).		
Likewise,	for	small	renal	tumours	≤	4	cm	CEUS	achieved	a	median	sensitivity	of	91%	
and	specificity	of	76%	[23,	51],	whereas	CT	only	reached	85%	and	64%	[18,	21,	23].	
Furthermore,	in	the	differentiation	of	RCC	from	AML	CEUS	reached	very	high	median	
sensitivity	and	specificity	values	of	89%	and	96%	[51-53].		
One	study	[54]	examined	CEUS	in	the	prediction	of	papillary	RCC	(pRCC),	reaching	a	
mediocre	sensitivity	of	53%	combined	with	excellent	specificity	(97%).	
Another	study	[30]	 investigated	CEUS	 in	the	detection	of	renal	vein	 invasion.	 In	a	
population	with	12	patients	displaying	renal	vein	invasion	out	of	106	patients	with	
RCC,	 CEUS	was	 able	 to	 achieve	 sensitivity	 and	 specificity	 values	 of	 83%	and	96%	
respectively.		
	
Table	6:	CEUS	-	Summary	of	diagnostic	accuracy	
	
Study	 Intervention	 Sensitivity	 Specificity	
Chen	2015	 CEUS	 89%	 81%	
Ignee	2010	 CEUS	 97%	 45%	
Jiang	2008	 CEUS	 100%	 64%	
Li	2011	 CEUS	 93%	 71%	
Li	2013	 CEUS	 93%	 97%	
Quaia	2008	 CEUS	 89%	 74%	
Tamai	2005	 CEUS	 94%	 46%	
Xu	2010	 CEUS	 88%	 97%	
Xue	2015	 CEUS	 53%	 97%	
Yuan	2011	 CEUS	 96%	 57%	
Median	(+/-	IQR)	 93%	(88.75	-	
98.25%)	
72.5%	(54	-	
97%)	
	
	
	
The	 use	 of	 PET/CT	 in	 the	 characterisation	 of	 renal	masses	was	 evaluated	 in	 four	
different	 studies	 [19,	 55-57].	 They	 all	 reported	 high	 diagnostic	 accuracy	 for	 the	
differentiation	of	RCC	from	other	benign	and	malignant	renal	masses.		
Two	studies	[55,	57]	used	18F-FDG	as	a	tracer.	They	reported	a	median	sensitivity	of	
88%	(range	86%-90%)	and	specificity	of	87.5%	(range	75%-100%).	Size	and	grade	of	
3.2.4	PET/CT	
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FDG-positive	tumours	was	found	to	be	higher	than	those	of	FDG-negative	lesions.	
However,	sample	sizes	were	low	with	19	and	30	patients	respectively.	
One	multi-centre	study	[19]	compared	the	diagnostic	accuracy	of	124I-girentuximab	
PET/CT	 with	 that	 of	 contrast-enhanced	 CT.	 Recruiting	 a	 large	 population	 of	 195	
patients	with	a	wide	variety	of	renal	tumours,	PET/CT	was	able	to	attain	sensitivity	
and	specificity	values	of	86%	and	86%.	
For	 the	 differentiation	 of	 RCC	 and	 angiomyolipoma,	 another	 study	 [56]	 achieved	
excellent	diagnostic	accuracy	values	using	18F-FDG	and	11C-acetate	for	dual-tracer	
PET/CT.	All	AML	showed	negative	18F-FDG	but	increased	11C-acetate	metabolism	that	
was	significantly	higher	than	RCC.	Overall,	sensitivity	and	specificity	for	the	detection	
of	RCC	both	reached	90%.	For	the	diagnosis	of	angiomyolipoma	diagnostic	accuracy	
values	 even	 reached	 97%.	 Furthermore,	 different	 RCC	 subtypes	 could	 be	
differentiated	due	to	their	different	dual-tracer	metabolic	patterns.	
	
Table	7:	18F-FDG-PET/CT	-	Summary	of	diagnostic	accuracy	
	
Study	 Intervention	 Sensitivity	 Specificity	
Ak	2005	 18F-FDG-PET/CT	 86%	 75%	
Zhang	2012	 18F-FDG-PET/CT	 90%		 100%	
Median	 88%	 87.5%	
	
3.3	Subgroup	analysis	
	
A	 number	 of	 studies	 focused	 on	 specific	 questions	 within	 the	 broad	 topic	 of	
characterisation	of	renal	masses.	Some	only	included	certain	kinds	of	tumours,	such	
as	small	renal	masses	or	complex	cystic	renal	masses.	Others	specifically	investigated	
the	 differentiation	 of	 RCC	 from	 AML.	 Still	 others	 examined	 specific	 aspects	
concerning	the	staging	of	RCC.	
	
	
	
Six	studies	[18,	21,	23,	43,	46,	51]	examined	the	diagnostic	performance	of	CECT,	
CEUS	and	MRI	in	the	differentiation	of	small	renal	masses	(SRM)	≤	4	cm.	CECT	was	
3.3.1	Small	renal	masses	
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able	to	achieve	a	high	median	sensitivity	of	85%	(IQR	77.5-91%)	but	only	moderate	
median	specificity	of	79%	(IQR	52.5-88%)	[18,	21,	23].	In	contrast,	MRI	yielded	higher	
specificity	values	with	a	median	of	99%	(range	88%-100%)	[43,	46],	combined	with	
lower	sensitivity	(median	76%,	range	73%-81%).	CEUS	was	used	in	two	studies	[23,	
51]	that	rendered	excellent	sensitivity	(median	91%)	but	lower	specificity	(median	
76%).	
	
	
	
Another	four	studies	[20,	24,	26,	30]	reported	on	the	characterisation	of	cystic	renal	
masses.	Three	of	them	[20,	24,	30]	compared	the	diagnostic	accuracy	of	CEUS	to	
that	of	CECT	and/or	power	Doppler	ultrasound	(PDUS)	and	unenhanced	sonography.	
One	of	them	[26]	only	examined	the	use	of	CECT	in	the	differential	diagnosis	of	cystic	
renal	 masses	 without	 comparing	 it	 to	 CEUS.	 The	 papers	 examining	 CEUS	 stated	
excellent	sensitivity	values	with	a	median	of	94.5%	(range	89%-100%)	for	CEUS	that	
were	superior	to	those	of	CECT	(median:	86%,	range	67%-97%).	Median	specificity	
was	equally	lower	though	with	69%	(64%-74%)	for	CEUS	and	67%	(range	51%-86%)	
for	CECT.	
In	contrast,	diagnostic	accuracy	for	PDUS	and	unenhanced	sonography	were	poor	
[20,	24].			
	
	
	
The	discrimination	of	RCC	from	AML	in	particular	was	investigated	in	six	articles	[41,	
46,	 51-53,	 56].	Overall,	 they	were	 able	 to	 yield	 good	 results	with	 all	 the	 imaging	
modalities	that	were	used:	MRI,	PET/CT	and	CEUS.		
The	two	studies	examining	MR	only	included	AML	with	minimal	fat.	Accuracy	values	
displayed	quite	a	broad	range	with	a	median	sensitivity	of	81%	(range	73%-89%)	and	
specificity	of	82%	(range	65%-99%)	[41,	46].		
For	PET/CT	diagnostic	accuracy	was	slightly	higher	with	a	sensitivity	of	90%	and	a	
specificity	of	90%	[56].	Similarly,	for	CEUS,	median	sensitivity	and	specificity	reached	
89%	and	96%	[51-53]	in	this	set-up.	However,	the	slightly	higher	accuracy	values	for	
3.3.2	Complex	cystic	renal	masses	
3.3.3	Differentiation	of	renal	cell	carcinoma	from	angiomyolipoma	
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PET/CT	and	CEUS	could	be	due	to	the	fact	that	not	just	fat-free	AML	were	included.	
	
3.4	Staging	of	RCC	
	
Ten	studies	focused	on	questions	concerning	the	staging	of	RCC	[30,	33-40,	49].		
One	of	them	[33]	examined	the	use	of	MRI	and	CECT	for	the	general	staging	of	RCC.	
Both	 imaging	 techniques	 achieved	 good	 results	with	 a	median	 sensitivity	 of	 87%	
(88%	and	86%	for	two	different	readers)	and	specificity	of	74.5%	(72%/77%)	for	CT	
and	a	median	sensitivity	of	90%	(91%/89%)	and	specificity	of	75%	(83%/67%)	using	
MRI.	
Two	articles	[34,	35]	 investigated	the	detection	of	tumour	thrombus	 in	RCC	using	
CECT,	 MRI	 and	 colour	 Doppler	 ultrasound.	 CECT	 was	 used	 in	 both	 studies,	 but	
yielded	 varying	 results	 with	 a	 median	 sensitivity	 of	 77.5%	 (range	 62-93%)	 and	
specificity	of	81%	 (range	80-82%).	MRI	was	able	 to	attain	a	median	 sensitivity	of	
92.5%	(85%	and	100%	for	two	different	readers),	but	with	slightly	lower	specificity	
of	75%	[34].	However,	colour	Doppler	ultrasound	was	superior	to	both	MRI	and	CECT	
with	a	sensitivity	of	96%	and	specificity	of	95%	[35].	
Seven	of	the	studies	[30,	36-40,	49]	examined	the	invasion	of	structures	adjacent	to	
the	kidneys,	such	as	perinephric	fat,	collecting	system,	renal	vein	or	renal	sinus	fat.		
Regarding	 perinephric	 fat	 invasion,	 three	 studies	 [36-38]	 found	 CECT	 to	 provide	
satisfactory	median	sensitivity	of	76%	(IQR	68.25%-83.75%)	and	specificity	of	71.5%	
(IQR	 59.75%-71.5%).	 MRI	 was	 able	 to	 yield	 similar	 sensitivity	 (72%)	 but	 higher	
specificity	(93%)	[36].		
Concerning	 muscular	 venous	 branch	 invasion,	 two	 studies	 [39,	 49]	 reported	
excellent	sensitivity	for	both	CECT	(94%)	[39]	and	MRI	(100%)	[49]	combined	with	
poor	specificity	(30%	vs.	42%).	
Using	 CECT	 for	 the	 diagnosis	 of	 collecting	 system	 invasion,	 one	 study	 [40]	 even	
stated	diagnostic	accuracy	values	of	100%.	
In	the	diagnosis	of	renal	vein	invasion,	two	studies	[30,	38]	found	CEUS	to	be	superior	
to	CECT	concerning	sensitivity	(83%	vs.	median	of	59%),	while	specificity	values	were	
almost	identical	(96%	vs.	median	of	93%).	
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Regarding	sinus	fat	invasion,	two	papers	[37,	38]	reported	high	sensitivity	(median	
88%)	along	with	mediocre	specificity	(median	71%)	for	CECT,	whereas	MRI	achieved	
a	sensitivity	of	100%	and	specificity	of	94%	in	one	study	[49].	
	
3.5	Risk	of	bias	
	
Quality	and	risk	of	bias	of	the	included	studies	was	assessed	using	the	QUADAS-2	
tool	[16].	QUADAS-2	is	composed	of	four	domains	including	patient	selection,	index	
test,	reference	standard	and	flow	and	timing.	A	summary	of	the	results	can	be	seen	
in	figure	2.		
Overall,	there	was	a	large	number	of	cases	of	unclear	risk	of	bias,	where	information	
needed	 for	 the	assessment	was	not	mentioned	by	 the	studies.	For	 the	 reference	
standard	 in	 particular,	 only	 few	 studies	 reported	 whether	 the	 test	 results	 were	
interpreted	without	knowledge	of	the	index	test.	Even	though	this	may	seem	unlikely	
in	most	cases,	we	were	only	able	to	rate	the	risk	of	bias	“unclear”	in	this	domain	for	
these	papers.	
However,	 apart	 from	 these	 uncertain	 cases,	 risk	 of	 bias	 was	 rather	 low	 across	
studies.	In	the	domains	of	index	test,	reference	standard	and	flow	and	timing	there	
were	no	instances	of	high	risk	of	bias	at	all.	The	few	cases	that	were	rated	to	be	at	
high	risk	of	bias	resulted	from	ambiguities	in	patient	selection.	These	articles	did	not	
clarify	whether	 a	 consecutive	 or	 random	 sample	 of	 patients	was	 included	 and	 if	
inappropriate	exclusions	were	avoided.		
There	 were	 no	 concerns	 regarding	 applicability	 in	 any	 of	 the	 domains,	 probably	
owing	to	the	consistent	application	of	inclusion	and	exclusion	criteria	in	the	process	
of	study	selection.	
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4.	Discussion	
	
4.1	Summary	of	evidence	
	
According	to	the	current	EAU	guidelines	on	renal	cell	carcinoma	ultrasound,	CT	and	
MRI	are	the	traditional	imaging	techniques	for	the	characterisation	of	renal	masses	
and	 diagnosis	 of	 RCC.	 In	 most	 cases,	 renal	 masses	 are	 found	 incidentally	 on	
ultrasound	or	CT	and	are	then	further	evaluated	by	contrast-enhanced	CT.	If	there	
are	any	contraindications	to	CT	or	if	the	CT	results	are	indeterminate,	MRI	is	used	
for	further	analysis	[6].	
In	summary,	this	approach	is	substantiated	by	the	results	of	our	systematic	review.	
Both	CT	and	MRI	achieved	very	high	diagnostic	and	staging	accuracy	for	RCC	and	a	
number	of	other	renal	tumours.	Overall	median	sensitivity	for	the	diagnosis	of	RCC	
reached	88%	(IQR	81-94%)	for	CT	and	87.5%	(IQR	75.25-100%)	for	MRI.	The	median	
specificity	of	MRI	even	exceeded	that	of	CT	with	89%	(IQR	75%-96%)	vs.	75%	(IQR	
51%-90%).	This	may	justify	the	use	of	MRI	in	cases	of	indeterminate	imaging	results	
of	CT. 
As	for	the	staging	of	RCC,	both	imaging	modalities	rendered	high	accuracy	values,	as	
well.	For	CT,	median	staging	sensitivity	and	specificity	were	87%	and	74.5%,	while	
MRI	reached	a	median	sensitivity	of	90%	and	specificity	of	75%.	However,	for	more	
specific	questions	concerning	 the	 staging	and	exact	determination	of	 the	 tumour	
spread,	 different	 imaging	 techniques	 may	 be	 useful	 depending	 on	 the	 aspect	
examined.		
For	 ultrasound,	 the	 results	 varied	 strongly	 depending	 on	 the	 corresponding	
technique.	CEUS	was	able	to	achieve	excellent	overall	diagnostic	sensitivity	with	a	
median	 of	 93%	 (IQR	 88.75%-98.25%)	 in	 combination	 with	 mediocre	 median	
specificity	(72.5%,	IQR	54%-97%).	In	the	subgroup	of	complex	cystic	renal	masses,	
CEUS	proved	to	be	even	superior	to	CECT	with	a	median	sensitivity	of	94.5%	and	
specificity	of	69%	(vs.	86%	and	67%	for	CECT).	Furthermore,	CEUS	appeared	to	be	
useful	in	the	detection	of	renal	vein	invasion.	
The	diagnostic	performance	of	unenhanced	sonography	was	poor.	However,	it	has	
	 35	
to	be	kept	in	mind	that	the	majority	of	incidental	renal	masses	are	first	detected	on	
ultrasound	despite	its	modest	accuracy	[17].	Yet,	for	the	further	evaluation	of	these	
incidental	masses	other	imaging	modalities	are	required.	
For	PET/CT	diagnostic	accuracy	values	were	good,	but	based	on	only	a	small	amount	
of	data	available.	Here,	further	research	needs	to	be	done	in	order	to	draw	any	solid	
conclusions.	At	the	same	time,	the	high	radiation	exposure	of	PET/CT	has	to	be	taken	
into	account.	
The	subgroup	analyses	we	performed	displayed	high	sensitivity	for	CEUS	and	CECT	
in	the	characterisation	of	small	renal	masses	combined	with	lower	specificity.	The	
highest	specificity	values	in	this	subgroup	was	yielded	by	MRI.	These	results	suggest	
that	a	combination	of	imaging	methods	may	be	useful	in	the	differentiation	of	SRM,	
but	no	data	exist	if	this	combination	would	lead	to	a	higher	specificity	and	a	change	
in	the	workup	of	patients.	
	
4.2	Strengths	and	limitations	of	the	review	
	
The	implementation	of	this	systematic	review	adheres	to	the	PRISMA	guidelines	[14]	
and	Cochrane	review	on	diagnostic	test	accuracy	principles	[58].	It	summarises	the	
best	available	evidence	on	imaging	methods	for	the	diagnosis	and	staging	of	RCC.	
The	 PICO	 (population,	 intervention,	 comparison	 and	 outcomes)	 elements	 of	 the	
research	 question	 were	 developed	 by	 an	 expert	 panel	 of	 urologists	 (EAU	 RCC	
Guideline	 Panel).	 The	 strict	methodology	 of	 the	 entire	 review	makes	 the	 results	
reliable,	reproducible	and	transparent.	
However,	there	is	a	number	of	limitations	to	the	review.	The	strong	heterogeneity	
of	data	confined	us	to	a	narrative	synthesis	of	the	results,	making	a	meta-analysis	
impossible.	All	of	the	included	studies	were	retrospective.	About	half	of	them	were	
case	series	only	examining	one	imaging	modality,	the	other	half	were	comparative	
studies.	Many	of	the	studies	had	relatively	small	sample	sizes.	Due	to	the	incomplete	
retrieval	of	the	selected	abstracts	and	the	limitation	of	the	search	to	studies	from	
2000	onwards,	 important	publications	might	have	been	missed.	There	is	a	certain	
potential	 for	 selection	 bias	 in	 the	 process	 of	 study	 selection	 and	 for	 differential-
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verification	bias	due	to	variations	in	the	reference	standard	(e.g.	different	follow-up	
protocols).	 For	 some	 imaging	 modalities	 such	 as	 PET/CT	 and	 colour	 Doppler	
ultrasound	there	was	only	a	small	number	of	studies	available.	There	were	many	
cases	of	unclear	risk	of	bias	due	to	the	lack	of	information	on	certain	practices	of	the	
included	studies.	Hardly	any	of	the	studies	provided	information	on	the	influence	of	
imaging	results	on	therapeutic	interventions	or	overall	survival,	which	restricts	the	
potential	to	give	clinical	recommendations	based	on	the	results	of	the	studies.		
	
4.3	Factors	influencing	diagnostic	confidence	
	
Furthermore,	there	are	various	factors	that	influence	the	reliability	of	the	results	of	
each	included	study.		
First	 of	 all,	 there	 is	 a	 huge	 variety	 of	 different	 scanners,	 sequences,	 techniques,	
imaging	protocols,	contrast	mediums	and	technical	equipment	that	influences	the	
quality	of	the	images.	For	example,	the	heterogeneous	group	of	studies	investigating	
MRI	comprises	diffusion-weighted	(DW),	contrast-enhanced	(CE),	dynamic	contrast-
enhanced	(DCE),	blood	oxygen	 level	dependent	 (BOLD)	MRI	and	various	standard	
MR	 techniques.	 Studies	 examining	 contrast-enhanced	 CT	 used	 monophasic,	
biphasic,	triphasic	or	quadriphasic	techniques	with	single-	or	multidetector	scanners.	
This	heterogeneity	of	data	makes	it	hard	to	draw	general	conclusions.	
Secondly,	 the	 diagnostic	 yield	 is	 influenced	 by	 histologic	 features	 of	 the	 tumour.	
Different	studies	also	 included	different	subgroups	of	benign	and	malignant	renal	
masses,	focusing	on	different	aspects	and	challenges	in	the	imaging	of	renal	masses.	
Some	studies	focused	on	the	differentiation	of	different	subtypes	of	RCC,	whereas	
others	examined	the	accuracy	for	differentiating	RCC	from	certain	types	of	benign	
renal	tumours	such	as	AML	or	from	all	kinds	of	benign	renal	tumours.	Depending	on	
whether	“difficult”	differential	diagnoses	such	as	oncocytoma	and	AML	with	minimal	
fat	were	included	or	not,	diagnostic	accuracy	varied.	As	Choudhary	et	al.	[59]	and	
Israel	et	al.	[13]	have	stated,	renal	cell	carcinoma	cannot	be	reliably	differentiated	
from	oncocytoma	and	non-fat-containing	angiomyolipoma.		
Thirdly,	the	accuracy	depends	on	the	clinical	experience	as	well	as	on	the	physical	
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and	psychological	state	of	the	reader	[60].	Even	though	inter-rater	agreement	was	
good	across	studies,	differences	in	interpretation	of	imaging	features	remain.	This	is	
of	particular	interest	in	newer	ultrasound	techniques	such	as	CEUS,	which	are	mostly	
conducted	by	internists	or	urologists	themselves.	As	Seppala	et	al.	have	indicated,	
diagnostic	confidence	increases	with	the	experience	of	the	clinician	[61].	
	
4.4	Contraindications	and	side	effects	
	
Moreover,	not	every	imaging	technique	is	suitable	for	any	patient.	Contraindications	
for	 contrast-enhanced	 CT	 include	 allergies	 to	 contrast	 medium,	 pregnancy	 and	
thyroid	carcinoma.	But	also	for	MRI	certain	risks	and	contraindications	have	to	be	
considered.	 Apart	 from	 the	 interaction	 with	 pacemakers	 and	 all	 kinds	 of	
ferromagnetic	metals,	 the	potential	 side	effect	of	 gadolinium	contrast-associated	
nephrogenic	systemic	fibrosis	needs	to	be	kept	in	mind	[62].	Generally,	awareness	
of	the	high	radiation	exposure	not	only	of	CT,	but	even	more	so	of	PET/CT	is	crucial	
whenever	the	indication	for	further	imaging	is	introduced.		
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5.	Conclusions	
	
Contrast-enhanced	 CT	 and	 MRI	 remain	 the	 diagnostic	 mainstay	 for	 renal	 cell	
carcinoma	with	almost	equally	high	diagnostic	and	staging	accuracy.	Furthermore,	
there	is	evidence	for	an	increasing	significance	of	CEUS	in	the	future,	particularly	in	
the	subgroup	of	complex	cystic	renal	masses.	A	combination	of	CT	and	CEUS	or	MRI	
and	CEUS	can	be	useful	in	the	differential	diagnosis	of	unclear	renal	tumours.	Despite	
the	poor	diagnostic	accuracy	of	unenhanced	 sonography,	many	 renal	masses	are	
discovered	 incidentally	on	ultrasound.	Further	research	 is	 required	on	the	role	of	
PET/CT	in	the	characterisation	of	renal	masses.	
However,	because	of	the	moderate	methodological	quality	of	many	of	the	current	
studies,	 there	 is	a	need	 for	 future	well-designed	 large	prospective	studies	on	 the	
imaging	in	renal	masses	in	order	to	further	increase	the	quality	of	evidence.	
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Summary	
	
While	the	incidence	of	renal	cell	carcinoma	is	rising	in	most	countries	of	the	world,	
stabilisation	or	even	decrease	of	mortality	has	been	accomplished	in	many	countries	
of	Europe	and	North	America	 [1].	This	 can	be	explained	by	a	growing	number	of	
incidentally	detected	renal	masses	as	well	as	the	availability	of	improved	therapeutic	
measures	 in	many	Western	 countries	 [1,	 3].	However,	 for	 treatment	planning	an	
accurate	diagnosis	is	essential.	
The	 aim	 of	 this	 review	 is	 to	 systematically	 assess	 the	 diagnostic	 performance	 of	
contrast-enhanced	CT	in	comparison	to	other	imaging	modalities	for	diagnosing	and	
staging	RCC	in	adults.	Through	comprehensive	database	searching,	4593	abstracts	
matching	the	search	items	were	identified.	Out	of	these,	40	studies	comprising	4354	
patients	were	selected	for	data	extraction	and	analysis.	They	examined	four	major	
imaging	modalities	and	their	numerous	variations:	CT,	MRI,	PET/CT	and	ultrasound.		
In	summary,	both	CT	and	MRI	yielded	high	diagnostic	and	staging	accuracy	values.	
For	 ultrasound,	 the	 results	 varied	 strongly	 depending	 on	 the	 corresponding	
technique.	CEUS	was	able	to	achieve	excellent	overall	diagnostic	sensitivity	while	the	
diagnostic	performance	of	unenhanced	sonography	was	poor.	For	PET/CT	diagnostic	
accuracy	values	were	good,	but	based	on	only	a	small	amount	of	data	available.	For	
more	specific	questions	a	combination	of	different	imaging	techniques	such	as	CT	or	
MRI	and	CEUS	may	be	useful.		
However,	there	is	a	number	of	limitations	to	the	review.	All	of	the	included	studies	
were	 retrospective	and	about	half	of	 them	were	case	 series,	examining	only	one	
imaging	modality.	There	is	a	strong	heterogeneity	of	data	due	to	the	large	variety	in	
imaging	techniques	and	tumour	histotypes,	which	made	it	hard	to	draw	any	general	
conclusions.	 Hence,	 there	 is	 a	 need	 for	 future	 well-designed	 large	 prospective	
studies	on	the	 imaging	 in	renal	masses	 in	order	to	 further	 increase	the	quality	of	
evidence.	
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Zusammenfassung	
	
Bei	weltweit	steigender	Inzidenz	des	Nierenzellkarzinoms	konnte	in	vielen	Ländern	
Europas	 und	 Nordamerikas	 eine	 Stabilisierung	 oder	 sogar	 ein	 Rückgang	 der	
Mortalität	 erzielt	 werden	 [1].	 Grund	 dafür	 ist	 eine	wachsende	 Anzahl	 inzidentell	
diagnostizierter	renaler	Raumforderungen	bei	gleichzeitiger	Verfügbarkeit	besserer	
therapeutischer	 Möglichkeiten	 [1,	 3].	 Für	 die	 Therapieplanung	 ist	 eine	 präzise	
Diagnosestellung	jedoch	unerlässlich.		
Ziel	dieses	Reviews	 ist	es,	die	diagnostische	Leistung	von	Kontrastmittel-CT	 in	der	
Diagnostik	 sowie	 im	 Staging	 des	 Nierenzellkarzinoms	 beim	 Erwachsenen	 im	
Vergleich	mit	anderen	bildgebenden	Modalitäten	systematisch	auszuwerten.	
Durch	eine	umfassende	Literaturrecherche	in	elektronischen	Datenbanken	konnten	
4593	zu	unseren	Suchkriterien	passende	Abstracts	identifiziert	werden.	Aus	diesen	
wurden	40	Studien	mit	insgesamt	4354	Patienten	zur	Datenextraktion	und	Analyse	
ausgewählt.	Sie	untersuchten	vier	Haupt-Bildgebungsmodalitäten:	CT,	MRT,	PET/CT	
und	Ultraschall.	
Zusammenfassend	erbrachten	sowohl	CT	als	auch	MRT	beide	eine	ausgezeichnete	
Treffsicherheit	sowohl	in	Bezug	auf	Diagnosestellung	als	auch	bezüglich	Staging.	Im	
Hinblick	auf	die	Untersuchungen	mittels	Ultraschall	zeigte	sich	eine	hohe	Variabilität	
der	 Ergebnisse	 in	 Abhängigkeit	 von	 der	 verwendeten	Untersuchungstechnik.	 Der	
kontrastmittelgestützte	Ultraschall	konnte	eine	exzellente	diagnostische	Sensitivität	
erreichen,	 wohingegen	 die	 konventionelle	 Sonographie	 eine	 eher	 schwache	
diagnostische	 Reliabilität	 zeigte.	 PET/CT	 erreichte	 eine	 gute	 diagnostische	
Sensitivität	und	Spezifität,	die	jedoch	auf	einer	relativ	geringen	Anzahl	von	Studien	
beruhen.	 Für	 spezielle	 Fragestellungen	kann	auch	die	Kombination	verschiedener	
Bildgebungen	 sinnvoll	 sein,	 insbesondere	 die	 von	 CT	 oder	 MRT	 mit	 der	
Kontrastmittel-Sonographie.		
Es	 gilt	 jedoch	 zu	 bedenken,	 dass	 der	 Review	 einige	 Limitierungen	 aufweist.	 Alle	
eingeschlossenen	Studien	waren	retrospektiv	und	bei	etwa	der	Hälfte	handelt	es	sich	
um	 Fallserien	 mit	 nur	 einer	 Art	 von	 Bildgebung.	 Allgemeine	 Schlussfolgerungen	
wurden	durch	die	starke	Heterogenität	der	Daten	aufgrund	der	großen	Vielfalt	an	
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Bildgebungstechniken	 und	 Tumorhistologien	 erschwert.	 Es	 besteht	 daher	 ein	
umfangreicher	Bedarf	an	zukünftigen	großen	prospektiven	Studien,	um	die	Qualität	
der	Evidenz	weiter	zu	verbessern.	
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